Spokane, Washington – A New Study Led by Washington State University Researchers During the course of the COVID-19 pandemic, it has turned out to be much easier to get methadone treatment in Canada than in the United States.
Methadone is a drug used to combat the effects of opioid addiction and can help you quit stronger opiates such as heroin and fentanyl.
Using census data, the researchers found that the average American traveled an additional 11 miles to reach the nearest methadone clinic in the next 48 hours to reach the nearest clinic accepting new patients. I discovered that I had to travel another 25 miles.
Timely access to methadone is critical: even a day’s delay increases the likelihood of overdose, illicit opioid use, and the likelihood that people who need methadone will not seek treatment. has been pointed out in research.
“What we argue and argue, and we have been doing for a long time, is that the United States needs to look into other Western countries and how they provide methadone treatment. There is a need to consider adopting some of the policies around access to methadone treatment,” said Ofer Amram, assistant professor at Washington State University and lead author of the study. I’m here.
Amram also noted other differences that contribute to the US additions 106 drug overdose deaths per million people This includes the fact that new doses of methadone are available at local pharmacies once Canadians begin treatment.
“During treatment, methadone is available at your local pharmacy, so you don’t have to physically come to the clinic,” says Amram. “So in terms of access during treatment, Canada is much better.”
By comparison, in the United States, you must go to a methadone clinic 6 days a week to get a new dose for the first 90 days of treatment before you can get the right to take it at home.
During COVID-19, these restrictions were eased slightly, with those deemed ‘stable’ receiving up to 28 days of home care, and those deemed ‘unstable’ up to 14. Amram said there will be no adverse effects on patient outcomes as a result of these temporary policies and believes they should become law.
“This policy of deregulation should be considered for future adoption in the United States,” he said.